Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek Raghavan

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2017
Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research StatementKala Visvanathan, Laura A Levit, Derek Raghavan, et al.
The Lancet. Oncology|February 14, 2009
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataHoward I Scher, Xiaoyu Jia, Johann S de Bono, et al.
Investigational New Drugs|February 26, 2013
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancerRobert Dreicer, Jorge Garcia, Brian Rini, et al.
Human Pathology|October 30, 2020
Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneityClaud M Grigg, Chad Livasy, Jiaxian He, et al.
Endocrine-Related Cancer|August 4, 2020
Management changes for patients with endocrine-related cancers in the COVID-19 pandemicDerek Raghavan, Antoinette R Tan, E Shannon Story, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncologyLowell E Schnipper, Thomas J Smith, Derek Raghavan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2013
American Society of Clinical Oncology 2013 top five list in oncologyLowell E Schnipper, Gary H Lyman, Douglas W Blayney, et al.
JCO Oncology Practice|June 8, 2021
Levine Cancer Institute Financial Toxicity Tumor Board: A Potential Solution to an Emerging ProblemDerek Raghavan, Nicole A Keith, Hughes R Warden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2014
Reply to L.k. Griffeth et al and J.E. Battley et alLowell E Schnipper, Richard L Schilsky, J Russell Hoverman, et al.
Urologic Oncology|June 9, 2023
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sitesEarle F Burgess, Chad A Livasy, James T Symanowski, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2017
Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research StatementKala Visvanathan, Laura A Levit, Derek Raghavan, et al.
The Lancet. Oncology|February 14, 2009
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataHoward I Scher, Xiaoyu Jia, Johann S de Bono, et al.
Investigational New Drugs|February 26, 2013
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancerRobert Dreicer, Jorge Garcia, Brian Rini, et al.
Human Pathology|October 30, 2020
Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneityClaud M Grigg, Chad Livasy, Jiaxian He, et al.
Endocrine-Related Cancer|August 4, 2020
Management changes for patients with endocrine-related cancers in the COVID-19 pandemicDerek Raghavan, Antoinette R Tan, E Shannon Story, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncologyLowell E Schnipper, Thomas J Smith, Derek Raghavan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2013
American Society of Clinical Oncology 2013 top five list in oncologyLowell E Schnipper, Gary H Lyman, Douglas W Blayney, et al.
JCO Oncology Practice|June 8, 2021
Levine Cancer Institute Financial Toxicity Tumor Board: A Potential Solution to an Emerging ProblemDerek Raghavan, Nicole A Keith, Hughes R Warden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2014
Reply to L.k. Griffeth et al and J.E. Battley et alLowell E Schnipper, Richard L Schilsky, J Russell Hoverman, et al.
Urologic Oncology|June 9, 2023
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sitesEarle F Burgess, Chad A Livasy, James T Symanowski, et al.
Pageof 13